Treatment of apathy in Huntington's disease and other movement disorders

Current Treatment Options in Neurology

Volumn 13, Issue 5, 2011, Pages 508-519

  Krishnamoorthy, Ashok ^a   Craufurd, David ^b  

^a WREXHAM MAELOR HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ATOMOXETINE; BENSERAZIDE; BROMOCRIPTINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; LEVODOPA; METHYLPHENIDATE; MODAFINIL; PLACEBO; RIVASTIGMINE; SELEGILINE;

APATHY; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CHOREA; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; EMOTIONAL DISORDER; EVIDENCE BASED MEDICINE; HUMAN; HUNTINGTON CHOREA; INTERMETHOD COMPARISON; IRRITABILITY; MUSIC THERAPY; NARCOLEPSY; PARKINSON DISEASE; PSYCHOLOGIC ASSESSMENT; PSYCHOMOTOR ACTIVITY; SENSORY STIMULATION; SIDE EFFECT; SLEEP DISORDER; TREATMENT DURATION; TREATMENT PLANNING;

EID: 80755128156     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-011-0140-y     Document Type: Article

References (47)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971-83.
2. Watt DC, Seller A: A clinico-genetic study of psychiatric disorder in Huntington's chorea. Psychol Med Monogr SUPPL. 1993:23.
3. Cummings JL. Behavioral and psychiatric symptoms associated with Huntington's disease. In: Weiner WJ, Lang AE, editors. Behavioral neurology of movement disorders. New York: Raven; 1995. p. 179-86.
4. Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry. 2001;71:310-14. (Pubitemid 32772526)
5. Van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci. 2007;19:441-8. (Pubitemid 350156103)
6. Craufurd D, Thompson JC, Snowden JS. Behavioral changes in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(4):219-26. (Pubitemid 33051498)
7. Naarding P, Janzing JG, Eling P, van der Werf S, Kremer B. Apathy is not depression in Huntington's disease. J Neuropsychiatry Clin Neurosci. 2009;21(3):266-70. This article highlights the prevalence of depression and apathy in HD, and points out that these are different phenomena in HD. The authors have used standardized measures for diagnosing apathy and depression.
8. Rickards H, De Souza J, van Walsem M, van Duijn E, Simpson SA, Squitieri F, et al. The European Huntington's Disease network. Factor analysis of behavioural symptoms in Huntington's disease. J Neurol Neurosurg Psychiatry. 2011;82(4):411-2.
9. Marin RS, Wilkosz PA. Disorders of diminished motivation. J Head Trauma Rehabil. 2005;20:377-88. (Pubitemid 40923449)
10. Starkstein SE. Apathy and withdrawal. Int Psychogeriatr. 2000;12 SUPPL. 1:135-8.
11. Isella V, Melzi P, Grimaldi M, Iurlaro S, Piolti R Ferrarese C, et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov Disord. 2002;17(2):366-71. (Pubitemid 36041307)
12. Starkstein SE, Leentjens AF. The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatry. 2008;79(10):1088-92. In this article, the author describes diagnostic criteria for apathy, differential diagnosis, its relationship to cognitive disorders and depression, and the use of assessment scales.
13. Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006;16(7):916-28. (Pubitemid 43992442)
14. Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr. 2002;14(4):389-404. (Pubitemid 36331605)
15. Waldemar G, Gauthier S, Jones R, Wilkinson D, Cummings J, Lopez O, et al. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry. 2011;26(2):150-7.
16. Cubo E, Shannon KM, Tracy D, Jaglin JA, Bernard BA, Wuu J, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67(7):1268-71. (Pubitemid 44563842)
17. Gauthier S, Juby A, Dalziel W, Réhel B, Schecter R. EXPLORE investigators. Effects of rivastigmine on common symptomatology of Alzheimer's disease (EX-PLORE). CurrMed Res Opin. 2010;26(5):1149-60.
18. Rot U, Kobal J, Sever A, Pirtosek Z, Mesec A. Rivastigmine in the treatment of Huntington's disease. Eur J Neurol. 2002;9(6):689-90.
19. deTommaso M, Difruscolo O, Sciruicchio V, Specchio N, Livrea P. Two years' follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30(1):43-6. (Pubitemid 46204317)
20. Brodaty H, Woodward M, Boundy K, Barnes N, Allen G, NATURE Investigators. A naturalistic study of galantamine for Alzheimer's disease. CNS Drugs. 2006;20(11):935-43. (Pubitemid 44612715)
21. Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol. 2008;28(3):296-301.
22. Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, et al. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry. 2010;18(4):371-4. This is one of the very few trials (open-label) with apathy as a primary outcome measure. This study shows improvement in AES scores using methylphenidate over a 12-week period in Alzheimer's disease.
23. Spiegel DR Kim J, Greene K, Conner C, Zamfir D. Apathy due to cerebrovascular accidents successfully treated with methylphenidate: a case series. J Neuropsychiatry Clin Neurosci. 2009;21(2):216-9.
24. Keenan S, Mavaddat N, Iddon J, Pickard JD, Sahakian BJ. Effects of methylphenidate on cognition and apathy in normal pressure hydrocephalus: a case study and review. Br J Neurosurg. 2005;19(1):46-50. (Pubitemid 40824373)
25. Jansen IH, Olde Rikkert MG, Hulsbos HA, Hoefnagels WH. Toward individualized evidence-based medicine: five 'N of 1' trials of methylphenidate in geriatric patients. J Am Geriatr Soc. 2001;49:474-6. (Pubitemid 32390884)
26. Waugh JL, Miller VS, Chudnow RS, Dowling MM. Juvenile Huntington disease exacerbated by methylphenidate: case report. J Child Neurol. 2008;23(7):807-9. (Pubitemid 351998170)
27. Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord. 2009;24(2):277-82.
28. Weintraub D, Mavandadi S, Mamikonyan E, Siderowf AD, Duda JE, Hurtig HI, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75:448-55.
29. Beglinger LJ, Adams WH, Paulson H, Fiedorowicz JG, Langbehn DR, Duff K, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29(5):484-7.
30. Padala PR Burke WJ, Bhatia SC. Modafinil therapy for apathy in an elderly patient. Ann Pharmacother. 2007;41(2):346-9. (Pubitemid 46340067)
31. Czernecki V, Pillon B, Houeto JL, Pochon JB, Levy R, Dubois B. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia. 2002;40(13):2257-67. (Pubitemid 35303365)
32. Newburn G, Newburn D. Selegiline in the management of apathy following traumatic brain injury. Brain Inj. 2005;19(2):149-54. (Pubitemid 40259752)
33. Moutaouakil F, El Otmani H, Fadel H, Slassi I. Severe apathy following head injury: improvement with selegiline treatment. Neurochirurgie. 2009;55(6):551-4.
34. Van Reekum R, Bayley M, Garner S, Burke IM, Fawcett S, Hart A, et al. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj. 1995;9(1):49-53.
35. Kraus MF, Smith GS, Butters M, Donnell AJ, Dixon E, Yilong C, et al. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). Brain Inj. 2005;19(7):471-9. (Pubitemid 40852596)
36. O'Suilleabhain P, Dewey Jr RB. A randomized trial of amantadine in Huntington disease. Arch Neurol. 2003;60:996-8. (Pubitemid 36858360)
37. Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002;59(5):694-9.
38. Debette S, Kozlowski O, Steinling M, Rousseaux M. Levodopa and bromocriptine in hypoxic brain injury. J Neurol. 2002;249(12):1678-82. (Pubitemid 36269260)
39. Frattola L, Albiazzati MG, Spano PF, Trabucchi M. Treatment of Huntington's chorea with bromocriptine. Acta Neurol Scand. 1977;56(1):37-45. (Pubitemid 8116009)
40. Corcoran C, Wong ML, O'Keane V. Bupropion in the management of apathy. J Psychopharmacol. 2004;18(1):133-5. (Pubitemid 38623107)
41. Strassburger K, Andrich J, Saft C. Bupropion: first experience in Huntington's disease. J Neurol Neurosurg Psychiatry. 2008;79:A29-30.
42. Siniscalchi A, Gallelli L, Tolotta GA, Loiacono D, De Sarro G. Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis. Clin Ther. 2010;32(12):2030-4.
43. Hopman-Rock M, Staats PG, Tak EC, Dröes RM. The effects of a psychomotor activation programme for use in groups of cognitively impaired people in homes for the elderly. Int J Geriatr Psychiatry. 1999;14(8):633-42. (Pubitemid 29403282)
44. Ferrero-Arias J, Goñi-Imízcoz M, González-Bernal J, Lara-Ortega F, da Silva-González A, Díez-Lopez M. The efficacy of nonpharmacological treatment for dementia-related apathy. Alzheimer Dis Assoc Disord. 2011 Feb. 22 (Epub ahead of print).
45. Staal JA, Sacks A, Matheis R, Collier L, Calia T, Hanif H, et al. The effects of Snoezelen (multi-sensory behavior therapy) and psychiatric care on agitation, apathy, and activities of daily living in dementia patients on a short term geriatric psychiatric inpatient unit. Int J Psychiatry Med. 2007;37(4):357-70. (Pubitemid 351468860)
46. Raglio A, Bellelli G, Traficante D, Gianotti M, Ubezio MC, Villani D, et al. Efficacy of music therapy in the treatment of behavioral and psychiatric symptoms of dementia. Alzheimer Dis Assoc Disord. 2008;22(2):158-62.
47. Niu YX, Tan JP, Guan JQ, Zhang ZQ, Wang LN. Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer's disease: a randomized controlled trial. Clin Rehabil. 2010;24(12):1102-11. This trial of cognitive stimulation therapy for mild to moderate dementia specifically addressed outcomes of neuropsychiatric symptoms and found that only apathy and depression showed improvement. This study highlights the need for more studies of psychosocial interventions for apathy.